Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OmniAb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OmniAb's regulatory disclosures and financial reporting.
OmniAb, Inc. President and CEO Matthew W. Foehr reported multiple equity transactions on February 18, 2026. He acquired 58,333 shares of common stock through the vesting and exercise of restricted stock units (RSUs) and received new awards of 156,250 RSUs and 1,562,500 stock options.
The vested RSUs represent a grant that vests in three substantially equal annual installments beginning on February 18, 2026, while the new RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. The stock option grant becomes exercisable as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
To cover tax withholding obligations from the RSU vesting, 30,843 shares of common stock were sold at a weighted average price of $1.71 per share in transactions priced between $1.68 and $1.73. The filing states these are mandatory sell-to-cover transactions under the company’s equity incentive plans and not discretionary trades.
FOEHR MATTHEW W reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 93,670 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 4,375,787 shares.
GUSTAFSON KURT A reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 33,912 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 259,402 shares.
Berkman Charles S reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 34,074 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 383,623 shares.
OABI filed a notice that an insider plans to sell common shares under Rule 144. The filing lists planned sales of 20,483 and 30,451 common shares through Morgan Stanley Smith Barney, with aggregate market values of 34821.10 and 51766.70, respectively, on the NASDAQ on 02/17/2026 and 02/18/2026.
The shares come from restricted stock granted by the issuer as compensation, including 36,458 securities acquired on 02/16/2026 and 58,333 on 02/18/2026. The filing notes 143,955,400 common shares outstanding. It also discloses a prior sale of 13,666 common shares for gross proceeds of 26798.27 on 12/08/2025.
Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.
The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.
OABI insider Kurt A. Gustafson filed a notice of proposed sales under Rule 144 for common stock. The filing lists planned sales of 6,891 and 9,173 shares of common stock through Morgan Stanley Smith Barney on NASDAQ on 02/17/2026 and 02/18/2026, with aggregate market values of $11,714.70 and $15,594.10. The issuer had 143,955,400 shares of common stock outstanding. The shares to be sold were acquired as restricted stock compensation, including 13,542 shares on 02/16/2026 and 18,750 shares on 02/18/2026. The filing also notes a prior sale of 23,922 common shares on 12/08/2025 for gross proceeds of $46,909.73.
OmniAb, Inc. received an updated Schedule 13G/A showing that several related investment entities and individuals collectively hold meaningful passive stakes in its common stock. As of December 31, 2025, Robert Goldstein may have been deemed to beneficially own approximately 8.5% of OmniAb’s common shares, or 12,291,972 shares, through direct holdings and control positions in various entities. Ash X LP and its general partner RLG GP LLC each may have been deemed to beneficially own 7,557,202 shares, or about 5.3% of the company. RLG Capco II LLC may have been deemed to beneficially own 4,733,575 shares, or about 3.3%. Joel Greenblatt may have been deemed to beneficially own 1,429,766 shares, or about 1.0%. All percentages are based on 143,955,400 shares outstanding as of October 28, 2025. The reporting group certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of OmniAb.
OmniAb, Inc. director John L. Higgins reported the vesting of 13,172 restricted stock units (RSUs) and the corresponding acquisition of 13,172 shares of common stock on January 30, 2026.
The RSUs vest in three substantially equal annual installments beginning January 30, 2024, conditioned on his continued service. After this transaction, he beneficially owns 2,942,320 shares of common stock and 20,000 RSUs directly.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.